Compare Mesoblast Limited (MESO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Williams Companies Inc — how do they compare? Mesoblast Limited trades at $16.68 (market cap $2.21B), while Williams Companies Inc trades at $72.25 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 40× Mesoblast Limited's market cap, and Williams Companies Inc pays a 2.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | WMB | |
|---|---|---|
Market Cap | $2.21B | $88.45B |
Sector | Technology | Energy |
52-Week High | $20.96 | $79.40 |
52-Week Low | $12.88 | $56.51 |
Enterprise Value | $2.21B | $119.07B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Williams Companies (WMB) trades at $71.85, up 2.06% today, with a neutral technical signal and mixed earnings history. The company reported Q2 2026 EPS of $0.50, slightly missing estimates, but raised full-year EBITDA guidance. Recent news highlights the $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast presence and supporting long-term growth targets. Financials show strong profitability with a 25.18% net income margin and robust cash flow from operations of $5.90 billion in 2025.
Outlook remains positive with analyst consensus favoring Buy ratings (79.41%) and a $87.14 price target, though risks include execution of acquisitions and debt levels. The stock offers a dividend yield supported by stable cash flows, positioning it for growth in energy infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
